PT888309E - Derivados de imidazole que possuem afinidade para actividade de receptores de alfa2 - Google Patents

Derivados de imidazole que possuem afinidade para actividade de receptores de alfa2

Info

Publication number
PT888309E
PT888309E PT96932609T PT96932609T PT888309E PT 888309 E PT888309 E PT 888309E PT 96932609 T PT96932609 T PT 96932609T PT 96932609 T PT96932609 T PT 96932609T PT 888309 E PT888309 E PT 888309E
Authority
PT
Portugal
Prior art keywords
alkyl
hydrogen
different
affinity
alkoxy
Prior art date
Application number
PT96932609T
Other languages
English (en)
Inventor
Maire Marjatta Eloranta
Juha-Matti Savola
Siegfried Wurster
Victor Cockcroft
Arto Karjalainen
Paavo Huhtala
Maarit Hillila
Raino Saxlund
Arja Karjalainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of PT888309E publication Critical patent/PT888309E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
PT96932609T 1995-10-03 1996-10-02 Derivados de imidazole que possuem afinidade para actividade de receptores de alfa2 PT888309E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9520150.5A GB9520150D0 (en) 1995-10-03 1995-10-03 New imidazole derivatives

Publications (1)

Publication Number Publication Date
PT888309E true PT888309E (pt) 2003-07-31

Family

ID=10781676

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96932609T PT888309E (pt) 1995-10-03 1996-10-02 Derivados de imidazole que possuem afinidade para actividade de receptores de alfa2

Country Status (30)

Country Link
US (2) US6313311B1 (pt)
EP (1) EP0888309B1 (pt)
JP (1) JP4129891B2 (pt)
KR (1) KR19990064013A (pt)
CN (1) CN1068592C (pt)
AT (1) ATE234819T1 (pt)
AU (1) AU708002B2 (pt)
BG (1) BG63916B1 (pt)
CA (1) CA2231535C (pt)
CZ (1) CZ291576B6 (pt)
DE (1) DE69626862T2 (pt)
DK (1) DK0888309T3 (pt)
EE (1) EE04436B1 (pt)
ES (1) ES2195013T3 (pt)
GB (1) GB9520150D0 (pt)
HK (1) HK1014951A1 (pt)
HU (1) HU224197B1 (pt)
IL (1) IL123721A (pt)
LT (1) LT4460B (pt)
LV (1) LV12108B (pt)
NO (1) NO311024B1 (pt)
NZ (1) NZ319169A (pt)
PL (1) PL189110B1 (pt)
PT (1) PT888309E (pt)
RO (1) RO120409B1 (pt)
RU (1) RU2188194C2 (pt)
SI (1) SI9620111B (pt)
SK (1) SK283542B6 (pt)
UA (1) UA49847C2 (pt)
WO (1) WO1997012874A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
DE69823868T2 (de) * 1997-12-04 2005-04-21 Allergan Inc Substituierte imidazole derivate mit agonistischähnlicher wirkung auf die alpha 2b oder 2b/2c adrenergischen rezeptoren
AU2002254265B2 (en) * 1997-12-04 2008-05-15 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
EE200100193A (et) * 1998-09-28 2002-08-15 Orion Corporation 3-(1H-imidasool-4-ülmetüül)-indaan-5-ol'i kasutamine intraspinaalselt, teekasiseselt või epiduraalselt manustatava ravimi tootmises
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
EP1196168A2 (en) * 1999-06-25 2002-04-17 Orion Corporation Method of admistering an imidazole derivative to obtain analgesia
EP1223931B1 (en) * 1999-10-29 2005-12-14 Orion Corporation Use of a imidazole derivative for the treatment or prevention of hypotension and shock
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
PE20011321A1 (es) * 2000-05-08 2002-01-03 Orion Corp Indanilimizadoles policiclicos nuevos con actividad adrenergica alfa 2
TW200306783A (en) * 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
FR2839719B1 (fr) * 2002-05-16 2004-08-06 Pf Medicament Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
AR057771A1 (es) 2005-08-25 2007-12-19 Pharmacopeia Drug Discovery Agonistas adrenoreceptores alfa2c
KR20080039982A (ko) 2005-08-25 2008-05-07 쉐링 코포레이션 작용 선택적 알파2c 아드레날린성 수용체 효능제로서의이미다졸 유도체
EP1981499A1 (en) * 2006-01-27 2008-10-22 F.Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
EP2076497B1 (en) 2006-10-19 2012-02-22 F. Hoffmann-La Roche AG Aminomethyl-4-imidazoles
CN101535292A (zh) 2006-11-02 2009-09-16 弗·哈夫曼-拉罗切有限公司 作为痕量胺相关受体的调节剂的取代的2-咪唑类化合物
AU2007321376A1 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
ES2364701T3 (es) 2006-12-13 2011-09-12 F. Hoffmann-La Roche Ag Nuevos 2-imidazoles como ligandos para receptores asociados a aminas trazas.
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
AU2008209860A1 (en) 2007-02-02 2008-08-07 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as TAAR1 ligands for CNS disorders
US8470863B2 (en) 2007-02-13 2013-06-25 Merck Sharp & Dohme, Corp. Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists
CA2678072A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
RU2009134059A (ru) 2007-02-13 2011-03-20 Шеринг Корпорейшн (US) Функционально селективные агонисты альфа2с адренорецептора
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Taar1 리간드로서의 2-아미노옥사졸린
CA2691082A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
KR101150628B1 (ko) 2007-07-03 2012-05-31 에프. 호프만-라 로슈 아게 4-이미다졸린 및 항우울제로서 이의 용도
JP2010534701A (ja) 2007-07-27 2010-11-11 エフ.ホフマン−ラ ロシュ アーゲー Taarリガンドとしての2−アゼチジンメタンアミン及び2−ピロリジンメタンアミン
CA2695331A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8383818B2 (en) 2008-02-21 2013-02-26 Merck Sharp & Dohme Corp. Functionally selective alpha2C adrenoreceptor agonists
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
AU2010248776B2 (en) 2009-05-15 2013-06-06 Baudax Bio, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
SG11201403094TA (en) 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
CN104024250B (zh) 2012-01-12 2016-01-27 霍夫曼-拉罗奇有限公司 作为痕量胺相关受体(taar)的杂环衍生物
AU2013314388B2 (en) 2012-09-14 2016-07-14 F. Hoffmann-La Roche Ag Pyrazole carboxamide derivatives as TAAR modulators for use in the treatment of several disorders, such as depression, diabetes and Parkinson's disease
JP6027244B2 (ja) * 2012-09-17 2016-11-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリアゾールカルボキサミド誘導体
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
MX2016016190A (es) 2014-08-27 2017-03-08 Hoffmann La Roche Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central.
CN107001259B (zh) 2014-08-27 2019-12-06 豪夫迈·罗氏有限公司 作为taar配体的取代的氮杂环丁烷衍生物
ES2819830T3 (es) 2016-03-17 2021-04-19 Hoffmann La Roche Derivado de 5-etiol-4-metil-pirazol-3-carboxamida que tiene actividad como agonista de TAAR

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636002A (en) * 1969-12-15 1972-01-18 Janssen Pharmaceutica Nv 1-(2-halobenzyloxy-1-indanyl)-imidazoles
ES523609A0 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
US4634705A (en) * 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
US4659730A (en) * 1984-06-18 1987-04-21 Eli Lilly And Company Aromatase inhibiting imidazole derivatives
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
FI81092C (fi) * 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
US4878940A (en) * 1987-04-02 1989-11-07 Janssen Pharmaceutica N.V. Herbicidal 1,5-substituted 1H-imidazoles
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
GB9127050D0 (en) * 1991-12-20 1992-02-19 Orion Yhtymae Oy Substituted imidazole derivatives and their preparation and use
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives

Also Published As

Publication number Publication date
AU7132796A (en) 1997-04-28
CA2231535A1 (en) 1997-04-10
GB9520150D0 (en) 1995-12-06
UA49847C2 (uk) 2002-10-15
LV12108A (lv) 1998-08-20
CA2231535C (en) 2005-09-20
CN1068592C (zh) 2001-07-18
US6313311B1 (en) 2001-11-06
NO311024B1 (no) 2001-10-01
CN1198741A (zh) 1998-11-11
NO981496L (no) 1998-04-02
US20020007074A1 (en) 2002-01-17
JP4129891B2 (ja) 2008-08-06
DE69626862T2 (de) 2003-12-24
SI9620111B (en) 2001-12-31
EE9800101A (et) 1998-10-15
LT98057A (en) 1998-09-25
DE69626862D1 (de) 2003-04-24
US6479530B2 (en) 2002-11-12
CZ291576B6 (cs) 2003-04-16
AU708002B2 (en) 1999-07-29
HUP9802927A3 (en) 2003-02-28
NZ319169A (en) 1999-07-29
RU2188194C2 (ru) 2002-08-27
NO981496D0 (no) 1998-04-02
ATE234819T1 (de) 2003-04-15
WO1997012874A1 (en) 1997-04-10
CZ101898A3 (cs) 1998-09-16
LT4460B (lt) 1999-02-25
SK283542B6 (sk) 2003-09-11
PL328167A1 (en) 1999-01-18
SK43998A3 (en) 1998-10-07
EE04436B1 (et) 2005-02-15
IL123721A (en) 2004-07-25
DK0888309T3 (da) 2003-04-22
HUP9802927A2 (hu) 1999-10-28
LV12108B (en) 1998-10-20
JP2000507914A (ja) 2000-06-27
KR19990064013A (ko) 1999-07-26
IL123721A0 (en) 1998-10-30
HK1014951A1 (en) 1999-10-08
EP0888309A1 (en) 1999-01-07
EP0888309B1 (en) 2003-03-19
RO120409B1 (ro) 2006-01-30
BG102324A (en) 1999-01-29
PL189110B1 (pl) 2005-06-30
ES2195013T3 (es) 2003-12-01
SI9620111A (sl) 1998-10-31
BG63916B1 (bg) 2003-06-30
HU224197B1 (hu) 2005-06-28

Similar Documents

Publication Publication Date Title
PT888309E (pt) Derivados de imidazole que possuem afinidade para actividade de receptores de alfa2
MX9204139A (es) Nuevos derivados de bencimidazolona, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
RU98108027A (ru) Производные имидазола, обладающие аффинностью в отношении активности альфа2- рецепторов
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
YU85001A (sh) Derivati 5-fenil-pirimidina
KR880013886A (ko) 신규 알칸술폰아닐리드 유도체, 그의 제조방법 및 이를 함유하는 제약 조성물
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
PT1082116E (pt) Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento
ES2119454T3 (es) Derivados de pirrolidina para el tratamiento de los desordenes relacionados con la csk y la gastrina.
FR2633292B1 (fr) Nouveaux derives de la 20,21-dinoreburnamenine substitues en 15 par un groupement amine, leur procede de preparation et les intermediaires ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les reenfermant